330 related articles for article (PubMed ID: 26227068)
21. Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics.
Chua YA; Nazli SA; Rosman A; Kasim SS; Ibrahim KS; Md Radzi AB; Mohd Kasim NA; Nawawi H
J Atheroscler Thromb; 2023 Oct; 30(10):1317-1326. PubMed ID: 36567112
[TBL] [Abstract][Full Text] [Related]
22. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
23. Statin prescribing according to gender, age and indication: what about the benefit-risk balance?
Wallach-Kildemoes H; Stovring H; Holme Hansen E; Howse K; Pétursson H
J Eval Clin Pract; 2016 Apr; 22(2):235-46. PubMed ID: 26446680
[TBL] [Abstract][Full Text] [Related]
24. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.
Morrone D; Weintraub WS; Toth PP; Hanson ME; Lowe RS; Lin J; Shah AK; Tershakovec AM
Atherosclerosis; 2012 Aug; 223(2):251-61. PubMed ID: 22410123
[TBL] [Abstract][Full Text] [Related]
25. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
26. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
Cannon CP; Cariou B; Blom D; McKenney JM; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM;
Eur Heart J; 2015 May; 36(19):1186-94. PubMed ID: 25687353
[TBL] [Abstract][Full Text] [Related]
28. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
[TBL] [Abstract][Full Text] [Related]
29. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System).
Jia X; Ramsey DJ; Rifai MA; Ahmed ST; Akeroyd JM; Dixon DL; Gluckman TJ; Nambi V; Ballantyne CM; Petersen LA; Stone NJ; Virani SS
Am J Cardiol; 2020 Mar; 125(6):874-879. PubMed ID: 31952841
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
[TBL] [Abstract][Full Text] [Related]
31. Medication Adherence/Persistence and Demographics of Japanese Dyslipidemia Patients on Statin-Ezetimibe as a Separate Pill Combination Lipid-Lowering Therapy - An Observational Pharmacy Claims Database Study.
Umeda T; Hayashi A; Fujimoto G; Piao Y; Matsui N; Tokita S
Circ J; 2019 Jul; 83(8):1689-1697. PubMed ID: 31281135
[TBL] [Abstract][Full Text] [Related]
32. Variability in Plasma Lipids Between Intensive Statin Therapy and Conventional-Dose Statins Combined with Ezetimibe Therapy in Patients with Coronary Atherosclerosis Disease.
Jin J; Shan L; Wang M; Liu L; Xu T; Li D; Chen Z; Liu X; Zhang W; Li Y
Int Heart J; 2023 Sep; 64(5):807-815. PubMed ID: 37704407
[TBL] [Abstract][Full Text] [Related]
33. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study.
Jensen JS; Weeke PE; Bang LE; Høfsten DE; Ripa MS; Schjerning AM; Theilade JE; Køber LV; Gislason GH; Pallisgaard J
BMJ Open; 2019 Apr; 9(4):e022702. PubMed ID: 30940751
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway.
Cook JR; Yin D; Alemao E; Davies G; Krobot KJ; Veltri E; Lipka L; Badia X
Pharmacoeconomics; 2004; 22 Suppl 3():49-61. PubMed ID: 15669153
[TBL] [Abstract][Full Text] [Related]
37. Age, sex and practice variations in the use of statins in general practice in England and Wales.
Majeed A; Moser K; Maxwell R
J Public Health Med; 2000 Sep; 22(3):275-9. PubMed ID: 11077897
[TBL] [Abstract][Full Text] [Related]
38. Effect of an intervention to increase statin use in medicare members who qualified for a medication therapy management program.
Stockl KM; Tjioe D; Gong S; Stroup J; Harada AS; Lew HC
J Manag Care Pharm; 2008; 14(6):532-40. PubMed ID: 18693777
[TBL] [Abstract][Full Text] [Related]
39. Ezetimibe: a novel option for lowering cholesterol.
Davidson MH
Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
[TBL] [Abstract][Full Text] [Related]
40. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
Averna M; Missault L; Vaverkova H; Farnier M; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Taggart W; Brudi P
Diab Vasc Dis Res; 2011 Oct; 8(4):262-70. PubMed ID: 21859750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]